UTILITY Receives Qualified Infectious Disease Product Designation from the U.S. FDA
UTILITY therapeutics is focused on developing and commercialising antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development today.
About mecillinam/pivmecillinam
Mecillinam is a member of the penicillin subgroup of the β-lactam antibiotic class, a widely used class of antibacterial agents for the treatment of multiple serious infection types. It is available outside the US in both IV and oral formulations; the oral formulation contains the pro-drug pivmecillinam HCl, while the IV formulation contains the active drug mecillinam.
Pivmecillinam and mecillinam have been shown a good safety and efficacy profile for oral and parenteral use, respectively, through extensive clinical usage over 40 years. Currently, pivmecillinam tablets are approved in Europe, some Asiatic countries and some African countries for the treatment of uncomplicated UTI (uUTI, ie, acute uncomplicated cystitis) caused by bacteria susceptible to mecillinam.
Pivmecillinam is featured in the Infectious Diseases Society of America guidelines as a first line therapy for uncomplicated urinary tract infections, despite it not yet being available in the U.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180520005068/en/
Contacts
UTILITY therapeutics
Mark Beards, +44 203 930 9665
CEO
info@utilitytherapeutics.com
or
Consilium Strategic Communications
Mary-Jane Elliott, Ivar Milligan, Chris Welsh, +44 20 3709 5700
utility@consilium-comms.com
Source: UTILITY therapeutics Ltd